Treatment of fibroadenomatous hyperplasia in cats with aglépristone

Journal of Veterinary Internal Medicine

Volumn 16, Issue 6, 2002, Pages 710-713

  Gorlinger S ^a   Kooistra, H S ^a   Van Den Broek, A ^a   Okkens, A C ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Estrus prevention; Progesterone; Receptor antagonist

Indexed keywords

AGLEPRISTONE; ESTRANE DERIVATIVE; GESTAGEN; PROGESTERONE RECEPTOR;

ANIMAL; ANIMAL DISEASE; ARTICLE; CAT; CAT DISEASE; CLINICAL TRIAL; ENDOMETRITIS; EXPERIMENTAL NEOPLASM; FEMALE; FIBROADENOMA; HYPERPLASIA; OVARIECTOMY; PATHOLOGY; PREGNANCY; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; VETERINARY ABORTION;

ABORTION, VETERINARY; ANIMALS; CAT DISEASES; CATS; ENDOMETRITIS; ESTRENES; FEMALE; FIBROADENOMA; HYPERPLASIA; INJECTIONS, SUBCUTANEOUS; MAMMARY NEOPLASMS, ANIMAL; OVARIECTOMY; PREGNANCY; PROGESTINS; RECEPTORS, PROGESTERONE; TREATMENT OUTCOME;

EID: 0036834767     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2002.tb02412.x     Document Type: Article

References (26)

1. Hayden DW, Johnston SD, Kiang DT, et al. Feline mammary hypertrophy/fibroadenoma complex: Clinical and hormonal aspects. Am J Vet Res 1981;42:1699-1703.
2. Allen HL. Feline mammary hypertrophy. Vet Pathol 1973;10: 501-508.
3. Rutteman GR, Misdorp W. Hormonal background of canine and feline mammary tumours. J Reprod Fertil 1993;47:483-487.
4. Hayden DW, Johnson KH, Ghobrial HK. Ultrastructure of feline mammary hypertrophy. Vet Pathol 1983;20.254-264.
5. Misdorp W, Romijn A, Hart AAG. Feline mammary tumours: A case control study of hormonal factors. Anticancer Res 1991,11:1793-1798.
6. Misdorp W. Progestogens and mammary tumours in dogs and cats Acta Endocrinol 1991;125(Suppl 1):27-31.
7. Hinton M, Gaskell CJ Non-neoplactic mammary hypertrophy in the cat associated either with pregnancy or with oral progestogen therapy. Vet Rec 1977;100:277-280.
8. Hayden DW, Barnes DM, Johnson KH. Morphologic changes in the mammary gland of megestrol acetate-treated and untreated cats: A retrospective study. Vet Pathol 1989;26:104-113.
9. Rutteman GR, Blankenstein MA, Minke J, Misdorp W. Steroid receptors in mammary tumours of the cat. Acta Endocrinol 1991;125: 32-37.
10. Martín de las Mulas J, Millán Y, Bautista MJ. et al. Oestrogen and progesterone receptors in feline fibroadenomatous change: An immunohistochemical study. Res Vet Sci 2000;68:15-20.
11. Blendinger K, Bostedt H, Hoffmann B. Aborteinleitung und konservative Behandlung der Fibroadenomatose bei einer Katze unter Verwendung des Antigestagens RU 46534. Kleintierpraxis 1994;39: 495-499.
12. Wehrend A, Hospes R, Gruber AD. Treatment of feline mammary fibroadenomatous hyperplasia with a progesterone-antagonist. Vet Rec 2001;148:346-347.
13. Bethlehem M, Van der Luer RJT Felienc fibro-epitheliale hyperplaste bij drie gecastreerde katers na behandeling met progestativa. Tijdschr Diergeneeskd 1993;118:650-652.
14. Mandel M. Spontaneous remission of feline benign mammary hypertrophy. Vet Med Small Anim Clin 1975;70:846-847.
15. Spinale FG, Holzgrefe HH, Mukherjee R, et al. LV and myocyte structure and function after early recovery from tachycardia-induced cardiomyopathy. Am J Physiol 1995;268:836-847.
16. Galac S. The Effects of Aglepristone, the Progesterone Receptor Antagonist, on the Hypothalamic-Pituitary-Ovarian Axis, Pregnancy and Luteal Phase in Bitches. Ljubljana, Slovenia: University of Ljubljana, 2001. Thesis.
17. Galac S, Kooistra HS, Butinar J, et al. Termination of midgestation pregnancy in bitches with aglépristone, a progesterone receptor antagonist. Theriogenology 2000;53:941-950.
18. Verhage HG, Beamer NB, Brenner RM. Plasma levels of estradiol and progesterone in the cat during poly-estrus, pregnancy and pseudopregnancy. Biol Reprod 1976;14:579-585.
19. Feldman M, Ruan W, Cunningham BC, et al. Evidence that the growth hormone receptor mediates differentiation and development of the mammary gland. Endocrinology 1993;133:1602-1608.
20. Walden PD, Ruan W, Feldman M, Kleinberg DL. Evidence that the mammary fat pad mediates the action of growth hormone in mammary development. Endocrinology 1998;139:659-662.
21. Selman PJ, Mol JA, Rutteman GR, et al. Progestin-induced growth hormone excess in the dog originates in the mammary gland. Endocrinology 1994.134:287-292.
22. Mol JA, Van Garderen E, Selman PJ, et al. Growth hormone mRNA in mammary gland tumors of dogs and cats. J Clin Invest 1995; 95:2028-2034.
23. Mol JA, Van Garderen E, Rutteman GR, Rijnberk A. New insights in the molecular mechanism of progestin induced proliferation of mammary epithelium: Induction of the local biosynthesis of growth hormone (GH) in the mammary gland of dogs, cats and humans J Steroid Biochem Mol Biol 1996;57:67-71.
24. Mol JA, Selman PJ, Sprang EPM, et al. The role of progestins, insulin growth factor (IGF) and IGR-binding proteins in the normal and neoplastic mammary gland of the bitch: A review. J Reprod Fertil 1997;51(Suppl):339-344.
25. Van Garderen E, de Wit M, Voorhout WF, et al. Expression of growth hormone in canine and mammary tumors. Evidence for a potential autocrine/paracrine stimulatory loop. Am J Pathol 1997;150: 1037-1047.
26. Van der Burg B, Isbrucker L, van Selm-Miltenburg AJ. et al. Role of estrogen-induced insulin-like growth factors in the proliferation of human breast cancer cells. Cancer Res 1990;50:7770-7774.